Nurix Therapeutics Inc 's Income per employee grew in the third quarter 2026 on a trailing twelve month basis to , the contribution of Nurix Therapeutics Inc 's employees, reached a new high of $ 930,211income per employee. The Healthcare sector has seen employees of 212 other companies achieving higher income per employee. While Nurix Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 3662 to 3748.
Nurix Therapeutics, a leading biotech company based in San Francisco, recently announced the pricing of its upsized underwritten public offering of common stock. The company’s successful offering, which totaled $175 million in gross proceeds, reflects the strong investor interest in the biotech sector and Nurix’s promising pipeline of novel therapies. The offering, which included 10,166,667 shares of common stock priced at $15.00 per share, attracted a diverse group of investors eager to support Nurix’s innovative research and development efforts. In addition to common stock, Nurix also offered certain investors pre-funded warrants to purchase up to 1,500,100 shares of common stock at a purchase price of $14.999 per warrant.
Nurix Therapeutics Announces Proposed Public Offering Amidst Challenging Financial Performance SAN FRANCISCO, April 11, 2024 - Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein modulation drugs for cancer and inflammatory diseases, disclosed today its initiation of an underwritten public offering worth $125 million. The offering comprises both common stock and pre-funded warrants for shares of common stock, which will be offered and sold exclusively by Nurix. The company also plans to grant the underwriters a 30-day option to acquire additional shares at the public offering price, subject to market and other conditions. However, the completion, size, and terms of the offering remain uncertain. This announcement comes in the wake of Nurix Therapeutics recent financial performance. The company recorded a noteworthy cumulative net loss of $-144 million in the 12 months leading up to the fourth quarter of 2023. Unfortunately, this marks a deterioration in its overall ranking compared to the previous quarter, dropping from 517 to 922. While Nurix faces these challenges, the Major Pharmaceutical Preparations industry has witnessed multiple other companies achieving higher income per employee.
Companies with similar Income per Employee for 12 month ending Aug 31 2026, within Healthcare Sector
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
